Cosmos Health Inc. has launched a subscription-based purchasing model for its proprietary consumer health brands, beginning with NOOR Collagen in the United States. The initiative is designed to drive stronger customer loyalty, greater lifetime value, and more predictable cash-flow visibility. Early performance data indicates a repeat purchase rate above 60% and margins in excess of 50%.

The subscription model is currently live for NOOR Collagen, a proprietary product formulated with premium marine collagen tripeptide. The product is available in capsule form and is designed to support skin and joint health. The company reported that the initial response has been encouraging, with plans to extend the model to a broader range of its consumer health products across its brands and markets globally.

Cosmos Health expects the model to offer several benefits, including converting one-time purchases into recurring revenue, improving forward visibility into demand, and enabling product bundling. Additionally, subscribers will gain access to nutritionists and wellness consultants for personalized guidance. The company intends to provide further details on sales, retention rates, and margins as the model matures.

Key Metrics for NOOR Collagen Subscription Model

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group listed on NASDAQ under the ticker symbol COSM. The company focuses on developing and commercializing pharmaceutical and nutraceutical brands.

Cosmos Health Inc. has entered a distribution agreement with International Medical Company (IMC) to expand its Sky Premium Life product line in Qatar. IMC, which owns the largest pharmacy chain in the country, has placed an initial purchase order for 31,000 units. The partnership grants Cosmos Health immediate access to a broad consumer base through IMC's established nationwide retail network.

IMC, founded in 1998, is Qatar's fastest-growing pharmaceutical retailer and distributor. Its retail arm, Kulud Pharmacies, operates over 130 branches with a portfolio of more than 12,000 products. The company employs over 1,400 people across its Sales & Marketing, Pharmacy, and Consumer divisions.

Under the agreement, IMC will manage key functions in the territory, including sales and marketing, regulatory affairs, logistics, supply, and distribution. This move marks a further step in Cosmos Health's international expansion of Sky Premium Life across high-growth Gulf markets.

Greg Siokas, CEO of Cosmos Health, stated that Qatar is one of the Gulf's most dynamic healthcare markets. He emphasized that partnering with IMC and its Kulud Pharmacies network puts Sky Premium Life directly in front of consumers at scale from day one. Siokas noted that this aligns with the company's strategy to pursue high-impact partnerships to accelerate global growth.

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in 2009 in Nevada. The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub. Through its subsidiary Can Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.